UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

scPharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

810648105

(CUSIP Number)

November 21, 2017

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Item 1.

scPharmaceuticals Inc.

2400 District Avenue, Suite 310

Burlington, MA 01830

Item 2.

This Schedule 13G is being filed on behalf of each of the following persons:

Lundbeckfond Invest A/S (the “Lundbeckfond”)

Lene Skole (“Skole”)

Mette Kirstine Agger (“Agger”)

The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

Skole is the chief executive officer of Lundbeckfond. The directors of Lundbeckfond have delegated voting and dispositive power with respect to shares held by Lundbeckfond to Skole. Agger is the managing partner of Lundbeckfond and a member of the Board of Directors of the Issuer.

The business address for each Reporting Person is:

c/o Lundbeckfond Invest A/S

Scherfigsvej 7

DK-2100 Copenhagen, Denmark

Lundbeckfond is a private Danish corporation.

Each of Skole and Agger are citizens of Denmark.

Common Stock, par value $0.0001 per share

810648105

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(i) Sole power to vote or to direct the vote:

See row 5 of cover page for each Reporting Person.

(ii) Shared power to vote or to direct the vote:

See row 6 of cover page for each Reporting Person.

(iii) Sole power to dispose or to direct the disposition of:

See row 7 of cover page for each Reporting Person.

(iv) Shared power to dispose or to direct the disposition of:

See row 8 of cover page for each Reporting Person.

The approximate percentages of common stock reported as beneficially owned by the Reporting Persons are based upon 18,570,151 shares of common stock outstanding as of the completion of the Issuer’s offering of common stock and assuming the underwriters exercised their option to purchase an additional 960,000 shares, as reported on the Issuer’s Prospectus filed pursuant to Rule 424(b)(4) with the United States Securities and Exchange Commission on November 11, 2017.

Each of the Reporting Persons, except Lundbeckfond, disclaims beneficial ownership of the shares owned by Lundbeckfond, except to the extent of their respective pecuniary interests therein.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Under certain circumstances set forth in the governing documents of Lundbeckfond, the stockholders of Lundbeckfond may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

Material to be Filed as Exhibits.

Exhibit 1 – Agreement regarding filing of joint Schedule 13G.

Exhibit 2 – Power of Attorney.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2018

EXHIBIT 1

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of scPharmaceuticals Inc.

Date: February 13, 2018

EXHIBIT 2

POWER OF ATTORNEY

21 November 2017

Authorized signatures for Lundbeckfonden and Lundbeckfond Invest A/S

Signatures & Power of Attorney

The following persons are hereby authorized to sign - two in conjunction - for Lundbeckfonden (CVR no. 11814913) and Lundbeckfond Invest A/S (CVR no. 21855545) in all matters regarding our financial transactions in the ordinary course of business, including investments and other transactions in relation to Lundbeckfonden Ventures and/or Lundbeckfonden Emerge:

(1+2) or (1+3) or (1+4) as well as

(2+3) or (2+4) as well as

(3+4, save for transactions in relation to Lundbeckfonden Ventures and/or Lundbeckfonden Emerge),

1. Board of Trustees: (A-mandate):

2. Management: (A-mandate):

3. Other Management: (C-mandate):

4. Signatures together with the other management, management or Board of Trustees (B-mandate):

This Power of Attorney replaces the Power of Attorney dated February 2017 and is valid until it is withdrawn in writing.

On behalf of Lundbeckfonden / Lundbeckfond Invest A/S